U.S. Markets closed

[$$] European Equities Market Talk Roundup

1224 GMT - EKF Diagnostics could become a takeover target, says Panmure Gordon as it upgrades its recommendation on the medical-testing device developer to buy from hold. Panmure says it ultimately expects EKF to be bought at a comfortable premium to the current share price of 29 pence because profits are improving, the group is a robust cash generator and it is among only a few profitable companies with established point-of-care diagnostic products. “This increases its attractiveness to a potential acquirer,” Panmure’s Julie Simmonds says as she also raises her price target to 35 pence from 30 pence.